Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone

NCT04232761 · clinicaltrials.gov ↗

COMPLETED

Status

194

Enrollment

INDUSTRY

Sponsor class

Conditions

Castration-resistant Prostate Cancer

Interventions

DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)

Sponsor

Bayer